Skip to main content
SpringerLink
Log in

NANOTHERAPEUTICS

Nanotherapeutics for cardiovascular disease

  • News & Views
  • Published:

From Nature Reviews Cardiology

View current issue Sign up to alerts

Nanotherapies are emerging rapidly as options to treat cardiovascular disease. However, insufficient and heterogeneous delivery remain critical issues. Novel strategies to boost targeted delivery of systemically administered nanoparticles by optimizing the particle physical properties or using immune cells as carriers promise to increase nanotherapeutic effectiveness in cardiovascular and other inflammatory diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Systemic nanoparticle delivery strategies in vivo: free nanoparticles versus an immune cell ‘Trojan horse’.

References

  1. Fish, M. B. et al. Deformable microparticles for shuttling nanoparticles to the vascular wall. Sci. Adv. 7, eabe0143 (2021).

    Article  CAS  Google Scholar 

  2. Huang, S. S. et al. Immune cell shuttle for precise delivery of nanotherapeutics for heart disease and cancer. Sci. Adv. 7, eabf2400 (2021).

    Article  CAS  Google Scholar 

  3. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).

    Article  CAS  Google Scholar 

  4. Kanthi, Y., de la Zerda, A. & Smith, B. R. Nanotherapeutic shots through the heart of plaque. ACS Nano 14, 1236–1242 (2020).

    Article  CAS  Google Scholar 

  5. Smith, B. R. & Gambhir, S. S. Nanomaterials for in vivo imaging. Chem. Rev. 117, 901–986 (2017).

    Article  CAS  Google Scholar 

  6. Smith, B. R. et al. Real-time intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature. Nano Lett. 8, 2599–2606 (2008).

    Article  CAS  Google Scholar 

  7. Namdee, K., Thompson, A. J., Charoenphol, P. & Eniola-Adefeso, O. Margination propensity of vascular-targeted spheres from blood flow in a microfluidic model of human microvessels. Langmuir 29, 2530–2535 (2013).

    Article  CAS  Google Scholar 

  8. Smith, B. R. et al. Selective uptake of single walled carbon nanotubes by circulating monocytes for enhanced tumour delivery. Nat. Nanotechnol. 9, 481–487 (2014).

    Article  CAS  Google Scholar 

  9. Sofias, A. M. et al. Cyclic arginine–glycine–aspartate-decorated lipid nanoparticle targeting toward inflammatory lesions involves hitchhiking with phagocytes. Adv. Sci. 8, 2100370 (2021).

    Article  Google Scholar 

  10. Flores, A. M. et al. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis. Nat. Nanotechnol. 15, 154–161 (2020).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The author is grateful to the funding agencies AHA Transformational Project Award 18TPA34230113 and NIH grant R01 CA244491, and to Y. Zhang (MSU, USA) for initial figure preparation and A. Alessio for discussion (MSU, USA).

Author information

Authors and Affiliations

  1. Department of Biomedical Engineering and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA

    Bryan Ronain Smith

Authors
  1. Bryan Ronain Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bryan Ronain Smith.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Smith, B.R. Nanotherapeutics for cardiovascular disease. Nat Rev Cardiol 18, 617–618 (2021). https://doi.org/10.1038/s41569-021-00594-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-021-00594-5

  • Springer Nature Limited

This article is cited by

Search

Navigation